Don’t let winter ailments slow you down. Discover how understanding your symptoms can lead to powerful relief while embracing ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Recent studies have shown convincingly that vaccines against shingles (Herpes zoster) reduce the risk of dementia.

While respiratory syncytial virus (RSV) typically causes mild symptoms in adults, the virus can be life-threatening for infants. The seasonal virus is the most common cause of lower respiratory tract ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

Kennedy’s controversial panel overhaul met its first test. The result? A major win for public health ahead of RSV season.

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk for disease.

A prominent paediatrician on Sunday urged people to take more precautions against a common virus known as RSV, saying cases ...

A new study shows that a vaccine against respiratory syncytial virus is associated with a 29% reduction in dementia risk in ...